Our team
To know us better

Sean Robbins

Sean Robbins, Managing Partner, LatticePoint Sàrl has more than 15 years of experience in pricing and reimbursement in the pharmaceutical industry.
He has launched several products globally; and developed pricing and market access strategies for pharmaceutical products across the lifecycle. He has been a thought leader in developing strategies and tactics to combat International Reference Pricing; and providing advice to companies about what they can do to better prepare for reference pricing.  He is the author of several publications in clinical and health economics journals and has been involved in the development of pricing defense strategies for several of the early Biosimilars launched in Europe. He was an early advocate in instituting value-based selling programs to bring pricing and Key Account Management teams closer together to foster shared goals in pricing execution.  Sean is currently an Adjunct Assistant Professor at the University of Southern California in the Titus School of Pharmacy and Health Policy. Sean is passionate about introducing profit enhancing pricing analytics and decision tools into pharmaceutical and medical device companies to help drive improvements in company’s bottom line.

Managing Partner, LatticePoint Sàrl
Sean.Robbins (at)
Mobile: +41 79 611 35 66
Cours De Rive 13
1204 Geneva, Switzerland

Ted Haack

Ted Haack joined LatticePoint in July 2016 as Vice President.

He provides advisory services to early-stage genetic disease  companies and has advised on market access, EMA Adaptive Pathways, international expansion, talent acquisition, and key customer relationships.  Prior to consulting, he spent 17 years working in the pharmaceutical industry and headed the Market Access function for Genzyme’s Rare Disease Business Unit and Pfizer’s Head of Head of Market Access, Primary Care BU.  Before joining Pfizer, he spent 7 years at Schering-Plough in various regional and affiliate finance roles.  Ted began his career at Deloitte & Touche, including two years in Frankfurt, Germany and is a qualified SEC Audit Committee Financial Expert.  He has a BS degree in accounting from Villanova University, a Master of Arts in International Affairs from The Fletcher School of Law & Diplomacy at Tufts University, and an MBA from the Leonard N. Stern School of Business at New York University. He speaks fluent German in addition to his native English.

Carine Delattre

Carine Delattre has been working in LatticePoint since August
2014 as a Market Access and Pricing Consultant. 

Over a 6 years scientific career, Carine has worked in the fields of genomics, molecular biology, bioinformatics and oncology in the prestigious institutions of Swiss Institute of Technology (EPFL, Switzerland), Lausanne University hospital (CHUV), and the Broad Institute (MIT and Harvard, Boston, USA). She has authored several high-impact peer-reviewed scientific publications and developed GETprime, a database platform used by thousands of scientists.  Along her PhD thesis, she has received two gold medals and an award for her participation at the IGEM competition at MIT as an instructor for the EPFL Teams. Carine owns a PhD in Biotechnology and Bioengineering as well as a master of engineering from EPFL.

Marina Faiella

Marina Faiella has been working in LatticePoint since September
2014, as Market Access and Pricing consultant.

Before then, she spent a period in USA as member of the Center for Bio-Inspired Solar Fuel Production (BISfuel) and as a L’Óreal-UNESCO fellow, working on the solar to fuel energy conversion by using proteins. As post-doc researcher, she also worked in the Netherlands to find innovative and sustainable ways of producing plastic precursors, in cooperation with AkzoNobel. In 2010, she obtained her Ph.D. in Chemistry from the University of Napoli Federico II, focusing on the development of peptides to be used as analytical diagnostic tools, ad as potential drugs in antiangiogenic or anti-HIV therapy. During her academic career, she contributed to several scientific publications, and received prestigious awards and fellowships for her research.

Heinz Straessle

Heinz Straessle joined LatticePoint’s Pricing & Market Access team in January 2016 as a Research Associate.

In 2015, he finished his Master in Bioengeneering at the EPFL with a certification of excellence. For his Master thesis, he worked in the lab of Karen Christman at the Sanford Consortium for Regenerative Medicine / UCSD, where he created a biomaterial for cultivation of human beta cells. Heinz also conducted a study on the radiation protection in Cameroon for EssentialMed in 2014.

Pawel Kampczyk

Pawel Kampczyk joined LatticePoint Pricing & Market Access team in April 2016 as a Data Scientist Consultant.

Pawel is a data scientist experienced in the analysis of large and complex datasets in both business and scientific contexts. In 2011 he has obtained his Ph.D. in Astrophysics from ETH Zurich. As a PhD student and later as a Postdoctoral Researcher he was working in area of large galaxy surveys (SDSS, COSMOS, zCOSMOS) and observational cosmology. Using some of the biggest observational and theoretical datasets he has lead statistical analyses of galaxy populations through the cosmic time with a special focus on galaxy mergers. In 2014 he became a fellow of the first edition of S2DS (Science To Data Science) program in London. Since that time he has been helping businesses to understand their data.

Matthew Blackburn

Matthew Blackburn joined LatticePoint in April 2016 as a Market Access and Pricing Consultant.

In early 2016, he received his PhD in Biotechnology and at the Swiss Institute of Technology (EPFL, Switzerland), specializing in the integration of gene assembly with microfluidics for the rapid design, construction, cell-free expression and bioanalytical characterization of engineered proteins.  Prior to relocating to Switzerland, he received his Master of Science in Chemical Engineering from MIT (Cambridge, MA, USA) in 2010, contributing towards metagenomic research in environmental and human microbiomes. Throughout his academic career, Matthew has co-authored several scientific and received recognition for his research at various conferences (SynBio SEED2015 and Basel Life Science Week 2015), in addition to as an instructor for the EPFL iGEM teams in 2011 and 2012.

Natali Pennese

Natali Pennese joined LatticePoint in December 2016 as a Market access and pricing consultant.

Natali is a cell and molecular biologist holding a PhD in molecular life sciences from the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland. Specialized in human immunology, genetics and epigenetics, she has gathered over 10 years of biomedical research experience in multidisciplinary environments and has contributed to various fields ranging from tropical infectious diseases to cancer immunology, vaccines development, embryonic stem cell biology and human genomics. More recently, she has contributed to the design of business models and value propositions for innovative technologies coming from fundamental research in the genomics and transcriptomics areas. For this contribution, she was selected as one of the Venture Leaders 2016, a Swiss entrepreneurship program for the leaders of the 10 most promising business ideas in life sciences.

Cédric Lecureuil

Cédric Lecureuil joined LatticePoint’ Pricing & Market Access team in September 2014 as a Market Access Consultant.

For more than three years, he was previously a venture capital associate at Omnes Capital, where he has been actively involved in several investments (Gecko Biomedical, Enterome Biosciences, Pixium Vision, SpineGuard).  He holds a PhD in Immunology from Paris VI University during which he managed fundamental research on the interplay between chemokine receptors expressed on T cells and the HIV pathophysiology. He holds also an Advanced Master in Strategy and Management of International Business from the ESSEC Business School. Cédric started his career as an advisor in Innovation Management at Innovaction, a Paris based consulting firm. From 2009 to 2011, Cédric was analyst in the Life Sciences team at Ventech, a venture capital firm.